 Eyenovia, Inc. EYEN, a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has received subscriptions for a private placement in the amount of approximately 6.0 million of units at a price to the public of 2.21425 per unit. Each unit consists of i one share of common stock, par value 0.0001 per share, ii a one-year warrant to purchase 0.5 of a share of common stock, and iii a five-year warrant to purchase 0.75 of a share of common stock. The proceeds of the offering are expected to be used, together with other available funds, for the MicroLine and MicroPine clinical studies, to advance MicroStats new drug application, and for working capital and general corporate purposes. 